- Home
- HOWL vs CUE Comparison
HOWL vs CUE Comparison
Compare HOWL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- CUE
- Stock Information
- Founded
- HOWL 2017
- CUE 2014
- Country
- HOWL United States
- CUE United States
- Employees
- HOWL N/A
- CUE N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- CUE Health Care
- Exchange
- HOWL Nasdaq
- CUE Nasdaq
- Market Cap
- HOWL 47.1M
- CUE 52.8M
- IPO Year
- HOWL 2021
- CUE 2018
- Fundamental
- Price
- HOWL $1.32
- CUE $0.70
- Analyst Decision
- HOWL Strong Buy
- CUE Strong Buy
- Analyst Count
- HOWL 3
- CUE 3
- Target Price
- HOWL $8.33
- CUE $3.00
- AVG Volume (30 Days)
- HOWL 544.9K
- CUE 318.8K
- Earning Date
- HOWL 08-07-2025
- CUE 08-13-2025
- Dividend Yield
- HOWL N/A
- CUE N/A
- EPS Growth
- HOWL N/A
- CUE N/A
- EPS
- HOWL N/A
- CUE N/A
- Revenue
- HOWL $1,143,000.00
- CUE $7,991,000.00
- Revenue This Year
- HOWL N/A
- CUE N/A
- Revenue Next Year
- HOWL N/A
- CUE $23.84
- P/E Ratio
- HOWL N/A
- CUE N/A
- Revenue Growth
- HOWL N/A
- CUE 13.83
- 52 Week Low
- HOWL $0.60
- CUE $0.45
- 52 Week High
- HOWL $4.18
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- HOWL 62.41
- CUE 48.28
- Support Level
- HOWL $1.03
- CUE $0.71
- Resistance Level
- HOWL $1.10
- CUE $0.83
- Average True Range (ATR)
- HOWL 0.08
- CUE 0.07
- MACD
- HOWL 0.02
- CUE 0.00
- Stochastic Oscillator
- HOWL 82.40
- CUE 22.22
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.